Liposomal Formulations in Clinical Use: An Updated Review

被引：1614

作者：

Bulbake, Upendra ^{[1
]}

Doppalapudi, Sindhu ^{[1
]}

Kommineni, Nagavendra ^{[1
]}

Khan, Wahid ^{[1
]}

机构：

[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, Hyderabad 500037, Andhra Pradesh, India

来源：

PHARMACEUTICS | 2017年 / 9卷 / 02期

关键词：

liposomes; therapeutics; drug delivery; liposome technology; nanotechnology; clinical trials; marketed products; B COLLOIDAL DISPERSION; TOPOISOMERASE-I INHIBITOR; AMPHOTERICIN-B; PHASE-I; ENCAPSULATED DOXORUBICIN; TISSUE DISTRIBUTION; DRUG-DELIVERY; LIPID COMPLEX; CONVENTIONAL DOXORUBICIN; UNILAMELLAR VESICLES;

D O I：

10.3390/pharmaceutics9020012

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil (R), Ambisome (R), DepoDur (TM), etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam T Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.

引用

页数：33

共 154 条

[1]

Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies [J].

Adedoyin, A ;

Bernardo, JF ;

Swenson, CE ;

Bolsack, LE ;

Horwith, G ;

DeWit, S ;

Kelly, E ;

Klasterksy, J ;

Sculier, JP ;

DeValeriola, D ;

Anaissie, E ;

LopezBerestein, G ;

LlanosCuentas, A ;

Boyle, A ;

Branch, RA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2201-2208

[2]

Adler-Moore P.J., 1993, J LIPOSOME RES, V3, P429

[3]

Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: Pharmacokinetics in mice [J].

Ahmad, A ;

Wang, YF ;

Ahmad, I .

LIPOSOMES, PT E, 2005, 391 :176-185

[4]

Alam Masroor, 2005, Pain Pract, V5, P349, DOI 10.1111/j.1533-2500.2005.00048.x

[5]

ALBERTS DS, 1971, CLIN PHARMACOL THER, V12, P96

[6]

Allen T.M., 2004, SEMINARS ONCOLOGY

[7]

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects [J].

Alphandery, Edouard ;

Grand-Dewyse, Pierre ;

Lefevre, Raphael ;

Mandawala, Chalani ;

Durand-Dubief, Mickael .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (10) :1233-1255

[8]

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine [J].

Ambrosch, F ;

Wiedermann, G ;

Jonas, S ;

Althaus, B ;

Finkel, B ;

Gluck, R ;

Herzog, C .

VACCINE, 1997, 15 (11) :1209-1213

[9]

Anderson P., 2012, ANN ONCOLOGY

[10]

MIFAMURTIDE IN OSTEOSARCOMA-A PRACTICAL REVIEW [J].

Anderson, P. M. ;

Tomaras, M. ;

McConnell, K. .

DRUGS OF TODAY, 2010, 46 (05) :327-337

← 1 2 3 4 5 6 7 8 9 10 →